KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Cost of Revenue (2018 - 2025)

Historic Cost of Revenue for Ionis Pharmaceuticals (IONS) over the last 8 years, with Q3 2025 value amounting to $2.3 million.

  • Ionis Pharmaceuticals' Cost of Revenue rose 11830.07% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year increase of 1276.8%. This contributed to the annual value of $11.2 million for FY2024, which is 2279.65% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Cost of Revenue stood at $2.3 million for Q3 2025, which was up 11830.07% from $4.2 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Cost of Revenue peaked at $4.7 million during Q2 2022, and registered a low of $1.1 million during Q3 2024.
  • For the 5-year period, Ionis Pharmaceuticals' Cost of Revenue averaged around $2.8 million, with its median value being $2.6 million (2021).
  • Its Cost of Revenue has fluctuated over the past 5 years, first crashed by 6779.38% in 2023, then surged by 11830.07% in 2025.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Cost of Revenue stood at $2.2 million in 2021, then surged by 65.59% to $3.7 million in 2022, then fell by 16.93% to $3.1 million in 2023, then increased by 25.08% to $3.8 million in 2024, then tumbled by 38.96% to $2.3 million in 2025.
  • Its Cost of Revenue was $2.3 million in Q3 2025, compared to $4.2 million in Q2 2025 and $1.5 million in Q1 2025.